Home
Peptides & Proteins
Recombinant Proteins
Cytokines
Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant

Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant

Catalog No.

P1263

Skip to the beginning of the images gallery

Grouped product items
Size	Price	Stock
10ug	$99.00	Ship with 5-10 days
100ug	$407.00	Ship with 5-10 days
500ug	$912.00	Ship with 5-10 days

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background
Infomation
Quality Control

Background

The clinical use of the potent antitumor activity of TNF-αhas been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-αmutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-α, which binds to the murine TNF-R55 but not to the murine TNF-R75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-αmutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.

Reference

1. Davenport C, Kenny H, Ashley DT, et al. 2012. Eur J Clin Invest, 42: 1173-9

2. Cavalcanti YV, Brelaz MC, Neves JK, et al. 2012. Pulm Med, 2012: 745483

3. Sheng WS, Hu S, Ni HT, et al. 2005. J Leukoc Biol, 78: 1233-41

4. Berthold-Losleben MandHimmerich H. 2008. Curr Neuropharmacol, 6: 193-202.

Information

Gene ID	7124
Accession #	P01375
Alternate Names	Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin
Source	Escherichia coli.
M.Wt	Approximately 16.9 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, rHuTNF-α Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8
AA Sequence	MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F
Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.0.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Biological Activity	Fully biologically active when compared to standard. The ED₅₀ as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 10⁷ IU/mg in the presence of actinomycin D.
Shipping Condition	Gel pack.
Handling	Centrifuge the vial prior to opening.
Usage	For Research Use Only! Not to be used in humans.

Quality Control

Quality Control & DataSheet

View current batch:

Purity > 98 % by SDS-PAGE and HPLC analyses.
Endotoxin: Less than 1 EU/μg of rHu TNF-α/TNFSF2, Variant as determined by LAL method.

Datasheet

Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant

mRNA synthesis

Tyramide Signal Amplification (TSA)

Phos Binding Reagent Acrylamide

Cell Counting Kit-8 (CCK-8)

Inhibitor Cocktails

Background

Information

Quality Control

Quality Control & DataSheet

Product Catalog

Order Info

Customer Service

Contact Us

Newsletter

Follow Us